Via its US subsidiary Takeda America Holdings, Takeda Pharmaceutical has moved to strengthen its oncology pipeline by agreeing to acquire Intellikine for up to US$310 M, including US$190 M in cash upfront and up to US$120 M in potential clinical development milestone payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd